A collaborative agreement has been reached today between the Pharmacy Guild of Australia and Takeda that will resolve recent financial challenges faced by those with unused Vyvanse® on 1 December. It follows a PBS price change to $55 per unit across all strengths which was a significant reduction in value.
Under the agreed rebate arrangements, pharmacies can claim reimbursement for eligible Vyvanse® stock held prior to the price change, with claims processed through their preferred CSO-accredited wholesaler.
The approach will ensure continuity of patient care while recognising the vital role wholesalers play in Australia's medicines supply chain.
Pharmacies are advised to contact their preferred wholesaler by 31 December 2025 to confirm stock on hand as of 30 November 2025 for rebate eligibility.
The Guild's Health Economics and Policy Committee Chair, Anthony Tassone said the outcome reflected constructive engagement focused on fairness and sustainability.
"The Guild appreciates Takeda's willingness to work with us and acknowledge the real-world impact PBS price reductions can have on pharmacies, particularly when stock is held in good faith to support patients during ongoing ADHD medicine shortages," Mr Tassone said.
Takeda General Manager for Australia and New Zealand, Dave Peace, reaffirmed the company's commitment to supporting community pharmacy.
"Takeda values the critical role community pharmacists play in patient care. We recognise concerns raised following the 1 December list price change for Vyvanse® (lisdexamfetamine dimesilate) and are committed to ensuring pharmacies are not out of pocket," Mr Peace said.
Tassone continued, "We've seen great support from Takeda in addressing this issue for community pharmacies across the country and we welcome continued collaboration with manufacturers and wholesalers to support patient access and pharmacy sustainability – this agreement sets a new standard going forward.
"This situation was avoidable. We need better notice periods and better supply chain impact assessments for future PBS pricing changes and policy decisions – and we will continue to advocate for them."
